Australia markets closed

Allakos Inc. (ALLK)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.0300-0.0900 (-8.04%)
At close: 04:00PM EDT
1.0900 +0.06 (+5.83%)
After hours: 07:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.1200
Open1.1700
Bid0.9821 x 100
Ask1.0400 x 400
Day's range1.0000 - 1.1300
52-week range0.9800 - 5.6400
Volume754,742
Avg. volume457,712
Market cap91.201M
Beta (5Y monthly)0.91
PE ratio (TTM)N/A
EPS (TTM)-2.4600
Earnings date07 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2.90
  • GlobeNewswire

    Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria

    – Top-line Phase 1 CSU results expected at year end 2024 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK006 for the treatment of mast cell-driven diseases, today announced that the first patient with chronic spontaneous urticaria (CSU) has been dosed in a randomized, double-blind, placebo-controlled Phase 1 trial of AK006. The Phase 1 trial is designed to assess the safety, tolerability and pharmacokinetics of AK006, and t

  • GuruFocus.com

    Allakos Inc. Reports Increased Losses in Q1 2024, Misses Analyst Earnings Predictions

    Detailed Analysis of Financial Performance and Future Outlook

  • GlobeNewswire

    Allakos Provides Business Update and Reports First Quarter 2024 Financial Results

    SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2024. Recent Allakos Events Completed dosing in the single ascending dose (SAD) cohorts and multiple ascending dose (MAD) cohorts of the randomized, double-blind, placebo-controlled